[Vaccine] Information

Lorem ipsum dolor sit amet, consectetur adipiscing elit. In eleifend ullamcorper leo, at semper libero consectetur et. Ut eget ligula posuere, laoreet diam scelerisque, molestie ex. Phasellus pulvinar mollis lectus at volutpat. Mauris rhoncus hendrerit consectetur. In eu nunc in ligula suscipit pretium at non turpis. Quisque id augue non lectus bibendum consectetur. In ultricies erat in tristique porta. Morbi rhoncus diam id rhoncus scelerisque.

Additional Info


Lorem ipsum dolor sit amet.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. In eleifend ullamcorper leo, at semper libero consectetur et.

Nulla dapibus nisl quis consectetur rhoncus. Vestibulum non interdum elit, ut congue enim. Cras aliquet tellus lectus, rhoncus ornare mauris laoreet non. Quisque lacus nunc, suscipit vel tempus nec, porttitor eu erat. Phasellus lacinia vel sapien non tincidunt. Integer in elementum turpis. Vestibulum ante ipsum primis in faucibus orci luctus et ultrices posuere cubilia curae; In dapibus, ante ac fermentum elementum, nisl sem efficitur tortor, ac lacinia eros enim in odio.1

Lorem ipsum dolor sit amet, consectetur adipiscing elit. In eleifend ullamcorper leo, at semper libero consectetur et. Ut eget ligula posuere, laoreet diam scelerisque, molestie ex. Phasellus pulvinar mollis lectus at volutpat. Mauris rhoncus hendrerit consectetur. In eu nunc in ligula suscipit pretium at non turpis. Quisque id augue non lectus bibendum consectetur. In ultricies erat in tristique porta. Morbi rhoncus diam id rhoncus scelerisque.

Nulla dapibus nisl quis consectetur rhoncus. Vestibulum non interdum elit, ut congue enim. Cras aliquet tellus lectus, rhoncus ornare mauris laoreet non. Quisque lacus nunc, suscipit vel tempus nec, porttitor eu erat. Phasellus lacinia vel sapien non tincidunt. Integer in elementum turpis. Vestibulum ante ipsum primis in faucibus orci luctus et ultrices posuere cubilia curae; In dapibus, ante ac fermentum elementum, nisl sem efficitur tortor, ac lacinia eros enim in odio.

Lorem ipsum dolor sit amet.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. In eleifend ullamcorper leo, at semper libero consectetur et.

Nulla dapibus nisl quis consectetur rhoncus. Vestibulum non interdum elit, ut congue enim. Cras aliquet tellus lectus, rhoncus ornare mauris laoreet non. Quisque lacus nunc, suscipit vel tempus nec, porttitor eu erat. Phasellus lacinia vel sapien non tincidunt. Integer in elementum turpis. Vestibulum ante ipsum primis in faucibus orci luctus et ultrices posuere cubilia curae; In dapibus, ante ac fermentum elementum, nisl sem efficitur tortor, ac lacinia eros enim in odio.1

Lorem ipsum dolor sit amet, consectetur adipiscing elit. In eleifend ullamcorper leo, at semper libero consectetur et. Ut eget ligula posuere, laoreet diam scelerisque, molestie ex. Phasellus pulvinar mollis lectus at volutpat. Mauris rhoncus hendrerit consectetur. In eu nunc in ligula suscipit pretium at non turpis. Quisque id augue non lectus bibendum consectetur. In ultricies erat in tristique porta. Morbi rhoncus diam id rhoncus scelerisque.

Nulla dapibus nisl quis consectetur rhoncus. Vestibulum non interdum elit, ut congue enim. Cras aliquet tellus lectus, rhoncus ornare mauris laoreet non. Quisque lacus nunc, suscipit vel tempus nec, porttitor eu erat. Phasellus lacinia vel sapien non tincidunt. Integer in elementum turpis. Vestibulum ante ipsum primis in faucibus orci luctus et ultrices posuere cubilia curae; In dapibus, ante ac fermentum elementum, nisl sem efficitur tortor, ac lacinia eros enim in odio.


1. Rosenblum HG, Gee J, Liu R, et al. Safety of mRNA vaccines administered during the initial 6 months of the US COVID-19 vaccination programme: an observational study of reports to the Vaccine Adverse Event Reporting System and v-safe. Lancet. March 7, 2022. DOI:https://doi.org/10.1016/S1473-3099(22)00054-8.

2. U.S. Food and Drug Administration. FDA Approves First COVID-19 Vaccine. Available at: https://www.fda.gov/news-events/press-announcements/fda-approves-first-covid-19-vaccine.

3. Centers for Disease Control and Prevention (CDC). COVID-19 Vaccines for Children and Teens. June 19, 2022. Available at: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/children-teens.html

4. Centers for Disease Control and Prevention (CDC). Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States. March 2, 2022. Available at: https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html.

5. U.S. Food and Drug Administration. Coronavirus (COVID-19) Update: FDA Limits Use of Janssen COVID-19 Vaccine to Certain Individuals. May 5, 2022. Available at: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-limits-use-janssen-covid-19-vaccine-certain-individuals.

6. Centers for Disease Control and Prevention (CDC). Stay Up to Date with COVID-19 Vaccines Including Boosters. September 8, 2022. Available at: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/stay-up-to-date.html.

7. Centers for Disease Control and Prevention (CDC). New COVID-19 Vaccine Effectiveness Data Showcase Protection Gained by 3rd and 4th Doses. July 15, 2022. Available at: https://www.cdc.gov/media/releases/2022/s0715-COVID-VE.html.

8. Danza P, Koo TH, Haddix M, et al. SARS-CoV-2 Infection and Hospitalization Among Adults Aged ≥18 Years, by Vaccination Status, Before and During SARS-CoV-2 B.1.1.529 (Omicron) Variant Predominance — Los Angeles County, California, November 7, 2021–January 8, 2022. MMWR Morb Mortal Wkly Rep. 2022;71:177–181. DOI: http://dx.doi.org/10.15585/mmwr.mm7105e1.

9. Link-Gelles R, Levy ME, Gaglani M, et al. Effectiveness of 2, 3, and 4 COVID-19 mRNA Vaccine Doses Among Immunocompetent Adults During Periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 Sublineages Predominated — VISION Network, 10 States, December 2021–June 2022. MMWR Morb Mortal Wkly Rep. 2022;71:931–939. DOI: http://dx.doi.org/10.15585/mmwr.mm7129e1.

10. Kuodi P, Gorelik Y, Zayyad H, et al. Association between vaccination status and reported incidence of post-acute COVID-19 symptoms in Israel: a cross-sectional study of patients tested between March 2020 and November 2021. medRxiv. January 17, 2022. doi: https://doi.org/10.1101/2022.01.05.22268800.

11. Ayoubkhani D, Bermingham C, Pouwels KB, et al. Trajectory of long covid symptoms after covid-19 vaccination: community based cohort study. BMJ. 2022;377:e069676.

12. Taghioff SM, Slavin BR, Holton T, Singh D. Examining the potential benefits of the influenza vaccine against SARS-CoV-2: A retrospective cohort analysis of 74,754 patients. PLoS One. 2021;16(8):e0255541.

13. Tayar E, Abdeen S, Alah MA, et al. Effectiveness of influenza vaccination against SARS-Co-V-2 infection among healthcare workers in Qatar. Preprint at medRxiv: doi: https://doi.org/10.1101/2022.05.09.22274802.

Summary Block
This block has no content yet. Items you add to the page connected to this block will display here.

Latest Covid News and Resources

COVID-19 FAQs

For additional questions, consult with your health care provider.

Last updated September 29, 2022

Other Vaccine Information

  • Influenza

    Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aenean volutpat velit lorem, at pretium risus euismod eu. Donec quis lorem nec quam accumsan imperdiet.

  • Monkeypox

    Morbi ultricies sapien elit, non gravida justo rutrum at. In hac habitasse platea dictumst. Nunc a purus blandit, aliquam nulla sed, porta velit.

  • Work/Travel Related

    Aenean finibus quam ipsum, non rhoncus lectus fringilla non. Etiam sapien est, egestas vitae leo vehicula.

  • Other

    Laoreet finibus libero. Mauris tincidunt, ipsum at euismod venenatis, mi orci porttitor est, eget tincidunt risus diam quis lacus.